Evidence map›Paper›PMID 34671837›Full record

ReviewDer Pathologe2021

[Genetic evolution of in situ follicular neoplasia to t(14;18)-positive aggressive B-cell lymphoma].

A Vogelsberg, J Steinhilber, B Mankel, B Federmann, J Schmidt, I A Montes-Mojarro, K Hüttl, M Rodriguez-Pinilla, P Baskaran, S Nahnsen and 5 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Der Pathologe, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

A VogelsbergInstitut für Pathologie und Neuropathologie, Universitätsklinikum Tübingen, Tübingen, Deutschland. Antonio.Vogelsberg@med.uni-tuebingen.de.
J SteinhilberInstitut für Pathologie und Neuropathologie, Universitätsklinikum Tübingen, Tübingen, Deutschland.
B MankelInstitut für Pathologie und Neuropathologie, Universitätsklinikum Tübingen, Tübingen, Deutschland.
B FedermannInstitut für Pathologie und Neuropathologie, Universitätsklinikum Tübingen, Tübingen, Deutschland.
J SchmidtInstitut für Pathologie und Neuropathologie, Universitätsklinikum Tübingen, Tübingen, Deutschland.
I A Montes-MojarroInstitut für Pathologie und Neuropathologie, Universitätsklinikum Tübingen, Tübingen, Deutschland.
K HüttlAbteilung für Klinische Pathologie, Robert-Bosch-Krankenhaus und Dr. Margarete Fischer-Bosch-Institut für Klinische Pharmakologie, Stuttgart, Deutschland.
M Rodriguez-PinillaAbteilung für Pathologie, Fundación Jiménez Díaz, Madrid, Spanien.
P BaskaranZentrum für Quantitative Biologie, Eberhard Karls Universität Tübingen, Tübingen, Deutschland.
S NahnsenZentrum für Quantitative Biologie, Eberhard Karls Universität Tübingen, Tübingen, Deutschland.
M A PirisAbteilung für Pathologie, Fundación Jiménez Díaz, Madrid, Spanien.
G OttAbteilung für Klinische Pathologie, Robert-Bosch-Krankenhaus und Dr. Margarete Fischer-Bosch-Institut für Klinische Pharmakologie, Stuttgart, Deutschland.
L Quintanilla-MartinezInstitut für Pathologie und Neuropathologie, Universitätsklinikum Tübingen, Tübingen, Deutschland.
I BonzheimInstitut für Pathologie und Neuropathologie, Universitätsklinikum Tübingen, Tübingen, Deutschland.
F FendInstitut für Pathologie und Neuropathologie, Universitätsklinikum Tübingen, Tübingen, Deutschland.
Universitätsklinikum Tübingen · DEHospital Universitario Fundación Jiménez Díaz · ESUniversity of Tübingen · DEDr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology · DERobert Bosch Hospital · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn situ follicular neoplasia (ISFN) is a t(14;18)(q32;q21)

objectivesTo investigate the clonal evolution of ISFN to DLBCL - transformed from FL and de novo. MATERIALS AND

methodsIdentification of ISFN lesions in patients with DLBCL was performed by BCL2 staining of reactive lymphoid tissues. ISFN and DLBCL were subsequently analyzed by fluorescence in situ hybridization, clonality analyses, sequencing of the t(14;18) breakpoint, and targeted next-generation sequencing.

results10 cases with paired ISFN and DLBCL samples were identified, 6 of which were de novo DLBCL and 4 transformed from FL. 3 DLBCL carried MYC-rearrangements in addition to the t(14;18) and were classified as high-grade B‑cell lymphoma (HGBL). The clonal relationship of ISFN and DLBCL/HGBL was confirmed for all cases. CREBBP, KMT2D, EZH2, TNFRSF14, and BCL2 were the genes most frequently mutated, with the distribution of private and shared mutations pointing to 2 different scenarios of clonal evolution. In most cases, DLBCL/HGBL, ISFN, and, if also present, FL had evolved divergently from a common progenitor, whereas linear evolution was less frequent.

conclusionWe show for the first time that t(14;18)

Indexed as

Lymphoma, FollicularLymphoma, Large B-Cell, DiffuseEvolution, MolecularHumansIn Situ Hybridization, FluorescenceTranslocation, GeneticClonal evolutionDiffuse large B‑cell lymphomaFollicular lymphomaHigh-grade B‑cell lymphomaPrecursor lesion

Identifiers

PMID34671837
OpenAlexW3206423681

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.